| Product Name | ADARB1 Antibody |
|---|---|
| Description | Rabbit polyclonal antibody to ADARB1 |
| Synonyms | tibody; ADARB1 antibody; 1700057H01Rik antibody; ADAR2 antibody; ADAR2a antibody; ADAR2a L1 antibody; ADAR2a L2 antibody; ADAR2a L3 antibody; ADAR2b antibody; ADAR2c antibody; ADAR2d antibody; ADAR2g antibody; Adarb1 antibody; Adenosine deaminase; RNA specific; 2 antibody; Adenosine deaminase; RNA specific; B1 (homolog of rat RED1) antibody; Adenosine deaminase; RNA specific; B1 (RED1 homolog rat) antibody; Adenosine deaminase; RNA specific; B1 antibody; AW124433 antibody; AW558573 antibody; BB220382 antibody; D10Bwg0447e antibody; Double stranded RNA specific editase 1 antibody; Double-stranded RNA-specific editase 1 antibody; DRABA2 antibody; DRADA2 antibody; dsRNA adenosine deaminase antibody; EC 3.5.-.- antibody; Human dsRNA adenosine deaminase DRADA2 antibody; Human dsRNA adenosine deaminase DRADA2b; EC 3.5 antibody; OTTHUMP00000115341 antibody; OTTHUMP00000115342 antibody; RED 1 antibody; RED1_HUMAN antibody; RNA editase antibody; RNA editase 1 antibody; RNA editing deaminase 1 antibody; RNA editing enzyme 1 antibody; RNA editing enzyme 1; rat; homolog of antibody; RNA specific adenosine deaminase B1 antibody; RNA-editing deaminase 1 antibody; RNA-editing enzyme 1 antibody |
| Host | Rabbit |
| Clonality | Polyclonal |
| Conjugate | Unconjugated |
| Immunogen | Synthesized peptide derived from internal of human ADARB1. |
| Isotype | IgG |
| Target | ADARB1 |
| Reactivity | Human, Mouse, Rat |
| Applications | ELISA, WB |
| Form | liquid |
| Diluent Buffer | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Uniprot | P78563 |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
| Background |
Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis. Mittaz L., Genomics 41:210-217(1997). Lai F., Mol. Cell. Biol. 17:2413-2424(1997). Villard L., Somat. Cell Mol. Genet. 23:135-145(1997). |
| Supplier | Cusabio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
